The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
Top Cited Papers
- 21 August 2012
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 24 (2), 454-462
- https://doi.org/10.1093/annonc/mds329
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable CIPN were examined. Validity (correlation) and reliability studies were carried out. Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test–retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.Funding Information
- University of Milan Bicocca Rectoral Office
- Fondazione Banca del Monte di Lombardia
- Fondazione per la Ricerca Farmacologica Gianni Benzi
- Instituto de Salud Carlos III
- National Institute of Health/National Institute of Nursing Research (P30 NR011396)
This publication has 49 references indexed in Scilit:
- The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CASupportive Care in Cancer, 2011
- Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trialsSupportive Care in Cancer, 2010
- A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CASupportive Care in Cancer, 2010
- Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available toolsEuropean Journal of Cancer, 2010
- The Rasch measurement model in rheumatology: What is it and why use it? When should it be applied, and what should one look for in a Rasch paper?Arthritis Care & Research, 2007
- The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20European Journal of Cancer, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Quality of life research within the EORTC—the EORTC QLQ-C30European Journal Of Cancer, 2002
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Comparisons of Five Health Status Instruments for Orthopedic EvaluationMedical Care, 1990